Dr Joseph Gaut, Ladenson Professor of Pathology & Immunology at Washington University School of Medicine discusses his thoughts on the recently completed Phase II clinical trial of potravitug, a highly potent therapeutic antibody targeting BK polyomavirus (BKPyV) in kidney transplant recipients. Drawing on his extensive experience working with transplant patients, Dr Gaut explores the trial results, including the resolution of BKPyV nephropathy, BKPyV viral load reduction, and how potravitug could potentially address the significant unmet clinical need faced by transplant recipients. He also illuminates the challenges of current treatments, and the serious impact BKPyV infection can have on kidney graft functionality and overall patient survival.
